Transcript of Heart failure management toufiqur rahman
- 1. Dr. Md.Toufiqur Rahman MBBS, FCPS, MD, FACC, FESC, FRCPE,
FSCAI, FAPSC, FAPSIC, FAHA, FCCP, FRCPG Associate Professor of
Cardiology National Institute of Cardiovascular Diseases(NICVD),
Sher-e-Bangla Nagar, Dhaka-1207 Consultant, Medinova, Malibagh
branch Honorary Consultant, Apollo Hospitals, Dhaka and STS Life
Care Centre, Dhanmondi drtoufiq19711@yahoo.com CRT 2014 Washington
DC, USA
- 2. Definition Classification Patho physiology Stages of Heart
Failure Clinical Features Investigations Treatment
- 3. Definition Heart failure is a condition when heart fails to
meet the metabolic needs of the body provided the venous return is
adequate. Heart failure is a complex clinical syndrome that can
result from any structural or functional cardiac disorder that
impairs the ability of the ventricle to fill with or eject blood.
It has become an epidemic all over the world including our country.
As the life is prolonged with modern management of different
cardiovascular diseases, so is the chance of having more of heart
failure patients. Source: AHA/ACC Guideline, 2005 Source: ACC/AHA
2005 Guideline Update
- 4. Classification: Heart Failure may be classified as follows:
Depending on the time of onset: Acute Heart Failure: Accelerated
hypertension, AMI Chronic Heart Failure: Cardiomyopathy Depending
on the ventricle involved: Left Heart Failure: Systemic HTN, MS
Right Heart Failure: Cor-pulmonale, Pulmonary Embolism Source:
ACC/AHA 2005 Guideline Update
- 5. Classification Depending on the cardiac output: Low output
failure: Classic heart failure High output failure: Thyrotoxicosis,
Anemia Depending on the consequence of the heart failure: Forward
Failure-tissue hypoperfusion Backward failure-Congestive heart
failure Source: ACC/AHA 2005 Guideline Update
- 6. Pathophysiology Increased workload on Heart Activation of
Compensatory Mechanisms Compensated Heart Failure Self-defeating
Effects of Compensatory Mechanisms Decompensated Heart Failure
- 7. Compensatory Mechanisms Activation of neurohormonal system
Sympathetic Activation: Myocardial Contractility Herat Rate
Vasoconstriction Activation of RAS system : Vasoconstriction
Intravascular Volume (due to Na+ & fluid retention) Remodeling
of the ventricle: Hypertrophy Dilatation
- 8. How compensatory mechanisms are self-defeating? Sympathetic
activity -Energy expenditure Vasoconstriction- After load
Activation of RAS Preload-venous congestion ( backward failure)
Hypertrophy Death of cardiac cells Dilatation Wall stress
- 9. Etiology & Precipitating Factors Etiological factors:
Different causes of myocardial dysfunction Systolic
dysfunction-IHD, Cardiomyopathy Diastolic dysfunction-HTN, AS, HCM
Combined-IHD, Valvular diseases Sudden load on preserved
ventricular function Ruptured sinus of Valsalva-Acute LV failure
Acute pulmonary embolism - Acute RV failure
- 10. Precipitating Factors Precipitating factors: Anemia
Infection-RTI, UTI Arrhythmias Drugs- -blockers, Anti-arrhythmic,
Anti-cancer
- 11. How MS leads to Left & Right HF Mitral Steno sis
Increased LA pressure Increased pulmonary venous pressure Atrial
fibrillation Left heart failure Increased pulmonary arteriolar
pressure Pulmonary arterial HTN RV hypertrophy RV failure
Anemia/Infection
- 12. Stages of Heart Failure Source: ACC/AHA 2005 Guideline
Update Stage Criteria Example Stage-A At high risk for heart
failure but without structural heart disease or symptoms of HF.
Hypertension Coronary Artery Disease Diabetes Mellitus Cardiotoxins
Family history of cardiomyopathy Stage-B Structural heart disease
but without signs or symptoms of HF. Previous MI LV systolic
dysfunction Asymptomatic valvular disease Stage-C Structural heart
disease with prior or current symptoms of heart failure. Known
structural heart disease, Shortness of breath & fatigue,
Reduced exercise tolerance Stage-D Refractory HF requiring
specialized interventions. Patients who have marked symptoms at
rest despite maximal medical therapy
- 13. Cardinal Symptoms of Heart Failure 1. Undue tiredness 2.
Fatigability 3. Reduced exercise tolerance 4. Shortness of breath
5. Awakening from sleep at night 6. Swelling of the leg 1, 2 &
3 represent the features of Forward failure 4, 5, & 6
represents the features of Backward failure
- 14. Diagnosis of Heart Failure History: Physical examination:
Investigations: Routine: 1.CXR; 2. ECG; 3. Echocardiography; 4. CBC
Selective: 1. Cardiac cath; 2. Coronary angiogram;3. Renal function
test; 4. Thyroid function test; 5. Radionucliede study 6. Brain
Natriuretic Peptide (BNP): useful marker to identify the patient
with heart failure.
- 15. Management of Heart Failure: Principles: Treatment of heart
failure per se: Medical (pharmacological/interventional) treatment
Surgical treatment Electrical- ICD; Resynchronization Treatment of
the underlying causes: Correction of precipitating causes:
Objectives: To alleviate the symptoms To correct the underlying
cause To improve prognosis
- 16. Correction of Precipitating Causes: Control of the
infection Correction of the anemia Correction & prevention of
arrhythmias Withdrawal / substitution of offending drugs Treatment
of Underlying Causes: Revascularization for IHD Treatment of HTN
Treatment of valvular disease
- 17. Treatment of HF Treatment depends on the stage of heart
failure. -Treat HTN -Quit smoking -Treat lipid disorder -Encourage
exercise -Control of metabolic syndrome -Discourage alcohol intake
Drugs: -ACE inhibitors or ARB in appropriate patients Stage-A:
Stage-B: - Treat HTN -Quit smoking - Treat lipid disorder
-Encourage exercise - Discourage alcohol intake Drugs: - ACE
inhibitors or ARB in appropriate patients -Beta-blockers in
appropriate patients -Device-ICD
- 18. Treatment of HF Stage-C: -Treat HTN -Quit smoking -Treat
lipid disorder -Encourage exercise -Discourage alcohol intake
-Dietary sodium restriction Drugs for routine use: -Diuretics -ACE
inhibitors -Beta-blockers Drugs in selected patients: -Aldosterone
antagonists -ARB -Digitalis -Hydralazine/Nitrates Devices in
selected patients: -Biventricular pacing -ICD
- 19. Treatment of HF Stage-D: -Treat HTN -Quit smoking -Treat
lipid disorder -Encourage exercise -Discourage alcohol intake
-Dietary sodium restriction Options: Mechanical assist devices
Heart transplantation Continuous I.V inotropic infusion
Compassionate end of life care
- 20. Drugs Used in HF Management: Conventional Drugs: Diuretic-
Loop diuretics- Frusemide, Torsemide Thiazides-
Hydrochlorothiazide, Chlorthalidone,METOLAZONE Potassium sparing-
SPIRANOLACTONE, Triamterene,amioloride ACE Inhibitors-
Captopril,Lisinopril ARBS- Losartan, Valsartan Vasodilators
-Nitrates, Hydralizine Beta-blockers-Carvidolol,Metoprolol
Succinate Inotrops (Digoxin, Dobutamine, Noradrenaline)
- 21. Newer Drugs: Recombinant human type B natriuretic peptide
NESIRITIDE Neutral endopeptidase inhibitors: Omapatrilet,
Sampatrilet, Candoxatrilat Calcium sensitizers- Levosimendan
Nesiritide: Recombinant human B type natriuretic peptide Nesiritide
vs. Nitroglycerine: Nesiritide reduces right atrial pressure, PCWP,
cardiac index greater than Nitroglycerine. Offers greater relief of
dyspnoea than Nitroglycerine. Drugs Used in HF Management
- 22. Stem cell therapy Stem cell regeneration Replace or repair
myocardial cells using gene therapy Further Therapy
- 23. Drugs Symptomatic Relief Prognostic improvement Frusemide +
- Thiazide + - Spironolactone + + ACE inhibitors + + ARBs + +
Beta-blockers + + Digoxin + - Drugs for Heart Failure
- 24. MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in
Heart Failure) To see the effect of Metoprolol Succinate on
mortality, hospitalization & other clinical events in chronic
heart failure. 3991 patients; follow up I year. Dose 12.5- 25 mg/d
200mg/d Significantly fewer cardiovascular death compared with
placebo group. JAMA 2001
- 25. COMET (Carvedilol or Metoprolol European Trial): Purpose:
To compare the effects of Carvediol and Metoprolol on clinical
outcome in patients with heart failure. No. of patients: 3029
Treatment regimen: Carvedilol, titrated from 6.25mg to 25 mg b.i.d,
or Metoprolol Tertarate IR, titrated from 12.5 mg to 50mg b.i.d.
Result: In the Carvedilol group, 34% of patients died compared to
40% in the Metoprolol IR group. Lancet 2003
- 26. COPERNICUS (Carvedilol Prospective Randomized Cumulative
Survival Trial): To see the effects of Carvedilol on mortality in
patients with severe heart failure. No of patients: 2289 Treatment
regimen: Carvedilol 3.125 mg b. d 25mg b. d or placebo Result: 35%
decrease in the risk of death in the Carvedilol group NEJM
2001
- 27. CONSENSUS (Cooperative North Scandinavian Enalapril
Survival Study) : Purpose: To investigate the effect of Enalapril,
in addition to conventional therapy, on mortality in severe
congestive heart failure. No. of patients: 253 Treatment regimen:
Enalapril, 2.5mg/day up to 20 mg bid, or placebo. Result: Crude
mortality was reduced by 40% in the Enalapril group compared to
placebo group. AJC 1992
- 28. Purpose: To compare the effects of 2 Lisinopril dosages on
mortality and Morbidity in patients with chronic heart failure. No.
of patients: 3164 Treatment regime: Lisinopril, 2.5 or 5mg once
daily, plus Lisinopril, upto 30mg, or placebo once daily. Result:
Mortality was 8% lower in high-dose group than in low-dose group.
EHJ 1999 ATLAS (Assessment of Treatment with Lisinopril And
Survival):
- 29. ELITE II (Evaluation of Losartan In The Elderly): Purpose:
To compare the effects of Losartan or Captopril on all-cause
mortality &, secondary, on sudden cardiac death and/or
resuscitated cardiac arrest in patients with symptomatic Heart
failure. No. of patients: 3152 Treatment regimen: Losartan, 12.5mg
titrated as tolerated to 50mg once daily, or Captopril, 12.5 mg
titrated as tolerated to 50mg t. i. d. Result: No significant
differences in all-cause mortality, sudden death or resuscitated
cardiac arrest with slight favour for Losartan. Lancet 2000.
- 30. Val-HeFT(Valsartan Heart failure Trial) Purpose: To
investigate the effects of valsartan on mortality, morbidity and
quality of life in patients treated with ACEI Patients: 5010;
>18yrs, NYHA II- IV Dose: valsartan 40mg bd- 160mg bd Placebo
controlled Result: Significantly decreased mortality and morbidity;
improved NYHA class,EF,signs & symptoms of HF and quality of
life NEJM 2001
- 31. DIG (Digitalis Investigation Group) Purpose: To investigate
the effects of digoxin on mortality as well as on hospitalization
in heart failure patients No. of patients: 5548 Result: Digoxin in
low doses reduces hospitalization & mortality. EHJ 2006
- 32. Management of End-stage/ Refractory HF: When symptoms of
heart failure persist or experience rapid recurrence of symptoms
despite optimal medical therapy, these group of patients are
considered to have end- stage HF or refractory HF. Management:
Step-1: Hospitalization. Step-2: Low doses of a loop diuretic
combined with moderate dietary sodium restriction. Step-3:
Progressive increments in the doses of a loop diuretic &
frequently the addition of a second diuretic that has a
complementary mode of action. Step-4: Intravenous dopamine or
dobutamine.
- 33. Re-synchronization Therapy: In approximately 30% of
patients with heart failure, the disease process not only depresses
cardiac contractility but also affects the conduction pathway. Such
dyssyncrony has been associated with clinical instability and an
increased risk of death in patients with HF. Cardiac
re-synchronization reduces the degree of ventricular dyssyncrony,
increase in LVEF, decrease LV end-diastolic dimension and also
decrease in the magnitude of mitral regurgitation. As a result,
there occur significant improvement in functional capacity,
clinical status, and quality of life.
- 34. Indication of Cardiac Resynchronization Therapy Severe
heart failure (NYHA-III&IV) LBBB QRS width >120 msec.
Echocardiography :evidence of in coordinate LV contraction
- 35. Resynchronization
- 36. Cardiac Transplantation Severe symptomatic despite maximal
medical treatment. Freedom from other major diseases e.g., DM,
renal failure, malignancy, pulmonary disease. One year survival 90%
Five year survival 60%.
- 37. Heart failure is a disease of wide spectrum
Pathophysiologically heart failure is considered under a single
umbrella. Etiology and causes are so varied that heart failure
touches almost every chapter of cardiology.
- 38. Diagnostically, it is not a formidable problem,though
assessment of the course of the disease demands meticulous
observation and judgment from the physicians
- 39. Management of heart failure now progressed a long way and
still is evolving. There are so many options available that one
must be vigilant to keep pace with the evolving concepts of
management.
- 40. Recommendations for Biomarkers in HF
- 41. Recommendations for Noninvasive Cardiac Imaging
- 42. Recommendations for Invasive Evaluation
- 43. Recommendations for Treatment of Stage B HF
- 44. Stage C HFrEF: evidence-based, guideline-directed medical
therapy
- 45. Recommendations for Pharmacological Therapy for Management
of Stage C HFrEF.
- 46. Recommendations for Treatment of HFpEF
- 47. Recommendations for Device Therapy for Management of Stage
C HF.
- 48. Indications for CRT therapy algorithm
- 49. Recommendations for Inotropic Support, MCS, and Cardiac
Transplantation.
- 50. Stages in the development of HF and recommended therapy by
stage.
- 51. Classification of patients presenting with acutely
decompensated heart failure.
- 52. Recommendations for Therapies in the Hospitalized HF
Patient
- 53. Recommendations for Hospital Discharge
- 54. Pharmacological management of patients with newly
discovered AF. AF indicates atrial fibrillation; and HF, heart
failure.
- 55. Pharmacological management of patients with recurrent
paroxysmal AF. AF indicates atrial fibrillation.
- 56. Recommendations for Surgical/Percutaneous/Transcatheter
Interventional Treatments of HF.
- 57. Thank Youdrtoufiq19711@yahoo.com Asia Pacific Congress of
Hypertension, 2014, February Cebu city, Phillipines Seminar on
Management of Hypertension, Gulshan, Dhaka